Allergy.  1994 Jun;14(2):209-217.

What is the most important criteria in stopping inure otherapy in allergic asthmatics?

Abstract

Many studies reported on the effects of immunotherapy against aeroallogens in allergic asthmatics and its mechanisams. Immunotherapy produced a significant decrease in asthma symptom score and in various responses to allergens including decrease in early and late plase reactions to bronchoprovocation test, skin response to prick test, serum specific IgE level, and histamine releasibility from peripheral basophils. But it is uncertain what is the most important parameter to predict persistent remission after stopping immunotherapy. To evaluate the parameter to predict recurrence after stopping immunotherapy, we measured bronchilal responsiveness to aeroallergen(ABPT) and methacholine(MBP-T), skin responses, and serum specific IgE at the time of stopping immunotherapy and reevaluated them at 10-48 months after stopping IT. Among 5 patients who showed negative responses to MBPT, negative early and late reaction(EAR and LAR) to ABPT on stopping IT, 4 patients showed persistent negative response to MBPT and ABPT over follow-up period, and 1 patient showed positive EAR without symptomatic recurrence. 3 patients who showed positive MBPT, positive EAR, and negative LAR at stopping IT showed persistent remission and converted to negative response to MBPT. 3 patients who showed only positive EAR were also in persistent remission. And in a patient who showed only positive LAR at stopping IT, asthmatic symptom was recurred. In conclusion, it is suggested that disappearance of LAR to ABPT is the most important prognostic parameter in stopping IT.


MeSH Terms

Allergens
Asthma
Basophils
Ear
Follow-Up Studies
Histamine
Humans
Immunoglobulin E
Immunotherapy
Recurrence
Skin
Skin Tests
Allergens
Histamine
Immunoglobulin E
Full Text Links
  • ALG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr